Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of nutritional products company Martek Biosciences
So what: The latest quarter didn't turn out too bad, with revenue increasing to $119.1 million and adjusted earnings per share of $0.41, which topped estimates. What investors are focusing on is guidance for next quarter of $0.38 to $0.40 on revenue of $106 million to $110 million -- at the low side of expectations.
Now what: The market is handing out a drubbing after what looks like a very nice quarter. Guidance wasn't totally out of line, and considering the jump in sales, I think today provides a nice buying opportunity for investors. This Fool thinks that with Martek's forward price/earnings ratio of 13, there's plenty of upside potential for the company.
Interested in more info on Martek Biosciences? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.